Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06640972 · ClinicalTrials.gov registry record · Phase 2
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
A Phase 2 study of Triglycerides and Weight Gain Trajectory, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06640972: Completed Phase 2 study of Triglycerides and Weight Gain Trajectory, sponsored by Response Pharmaceuticals.
NCT06640972 is a Phase 2 study of Triglycerides and Weight Gain Trajectory that has completed, run by Response Pharmaceuticals. The registered enrollment target is 68 participants, roughly in line with the 69-participant average among 4 other Triglycerides trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06640972, a Phase 2 study of Triglycerides and Weight Gain Trajectory, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002. The main question it aims to answer is if treatment with RDX-002 will lower triglycerides after a high-fat meal in patients who have recently stopped treatment with semaglutide or tirzepatide for obesity. The trial will also examine the effect of RDX-002 on body weight and fasting levels of cholesterol. Researchers will compare RDX-002 to a placebo (a look-alike substance that contains no drug) to see if RDX-002 works to reduce triglycerides. Participants will: Take drug RDX-002 or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests
Primary Outcome
Mean percent change in incremental TG area under the curve (AUC) from baseline to week 12. Samples were collected at 0, 1, 2, 3, 4, 6, and 8-hours hours post dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RDX-002
Study Locations (1)
Minnesota
- Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2025-05-13 |
| Phase | Phase 2 |
What the finished NCT06640972 record still lists
NCT06640972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, roughly in line with the 69-participant average among 4 other Triglycerides trials with a reported enrollment target.
The record links to 3 conditions, with Triglycerides appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06640972 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06640972 about?
NCT06640972 is a clinical study titled "Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists". The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002. The main question it aims to answer is if treatment with RDX-002 will lower triglycerides after ...
What is the current status of trial NCT06640972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2024-09-27. Estimated completion is 2025-05-13.
What conditions does trial NCT06640972 study?
This clinical trial studies the following conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated.
What interventions are being tested in trial NCT06640972?
The interventions under investigation include: Placebo (DRUG), RDX-002 (DRUG).
Who is sponsoring clinical trial NCT06640972?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06640972 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triglycerides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
RECRUITING · NA
-
Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation
RECRUITING · NA
-
Effect of Diet on Vascular Disease in Pre-Menopausal Women
COMPLETED
-
Identifying Risk for Diabetes and Heart Disease in Women
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI